2 results
BioXmark liquid fiducial to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial
To test the feasibility and accuracy of BioXmark fiducial markers for IGRT based rectal tumor boosting.
Approved WMOCompleted
PrimaryTo evaluate confirmed ORR of Trastuzumab deruxtecan in human epidermal growth factor receptor 2- (HER2-) mutated NSCLC subjects treated at 5.4 and 6.4 mg/kg doses.Secundary- To evaluate the clinical efficacy of Trastuzumab deruxtecan at 5.4…